HealthDay News — About 30% of adults with severe mental illness (SMI) taking antipsychotic medications undergo diabetes-specific screening using validated screening measures, according to a study published online Nov. 9 in JAMA Internal Medicine.

Christina Mangurian, MD, from the University of California in San Francisco, and colleagues conducted a retrospective cohort study to examine diabetes screening among 50,915 publicly insured adults with SMI taking antipsychotic medications. The authors also examined characteristics predictive of screening. Data were examined during two study periods: Jan. 1, 2009, to Dec. 31, 2009, and Oct. 1, 2010, to Sept. 30, 2011.

TRENDING ON CPA: An Overview of ASRA Guidelines for Patients on Anticoagulants Undergoing Pain Procedures  

The researchers found that 30.1% of the cohort received diabetes-specific screening. In a yearlong period, 31.1% received no form of glucose screening. Having at least one outpatient primary care visit during the period examined was the strongest correlate of diabetes-specific screening (adjusted prevalence ratio, 1.8; P < 0.001).

Continue Reading

“Growing evidence supports the value of screening for diabetes mellitus in higher-risk populations, such as those receiving treatment with antipsychotic medications, including first-generation and second-generation agents that commonly result in co-occurring obesity,” the authors wrote. “Future studies should explore barriers to screening in this vulnerable population.”

One author disclosed financial ties to the pharmaceutical industry.


Mangurian C, Newcomer J, Vittinghoff E et al. Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications. JAMA Internal Medicine. 2015:1. doi:10.1001/jamainternmed.2015.6098.